A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants

Antivirals with broad coronavirus activity are important for treating high-risk individuals exposed to the constantly evolving SARS-CoV-2 variants of concern (VOCs) as well as emerging drug-resistant variants. We developed and characterized a novel class of active-site-directed 3-chymotrypsin-like p...

Full description

Bibliographic Details
Main Authors: Jimena Pérez-Vargas, Liam J. Worrall, Andrea D. Olmstead, Anh-Tien Ton, Jaeyong Lee, Ivan Villanueva, Connor A. H. Thompson, Svenja Dudek, Siobhan Ennis, Jason R. Smith, Tirosh Shapira, Joshua De Guzman, Shutong Gang, Fuqiang Ban, Marija Vuckovic, Michael Bielecki, Suzana Kovacic, Calem Kenward, Christopher Yee Hong, Danielle G. Gordon, Paul N. Levett, Mel Krajden, Richard Leduc, Pierre-Luc Boudreault, Masahiro Niikura, Mark Paetzel, Robert N. Young, Artem Cherkasov, Natalie C. J. Strynadka, François Jean
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
SARS-CoV-2 Omicron subvariants
SARS-CoV-2 3CLpro
3CLpro inhibitor
combination therapy
computer-aided drug design
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2246594

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2023.2246594

Similar Items